• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·002901.SZ
Share

Double Medical Technology Inc. Stocks

CN¥ 47.3Last Updated 14.07.2026

Issuer Rating

5/7
Performance

Average

Risk

Low

Recommendation

Hold

Market Cap

CN¥ 2.73B

CN¥ 47.3
Key Takeaways

Risk factor

Strong & resilient to price shocks

Data is available to registered users only
Data is available to registered users only

Profitability factor

Strong growth

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Double Medical Technology Inc. is a medical enterprise offering a diverse array of services, advanced technologies, and specialized devices. Primarily serving the Chinese market, its core competencies lie in orthopedics, wound management, neurosurgery, and general surgical solutions. The company also boasts an international footprint, distributing its products to approximately 50 countries and regions worldwide, including the European Union, Russia, South America, Australia, Southeast Asia, the Middle East, and South Africa. Founded in 2004 under its previous name, Xiamen Da Bo Ying Jing Medical Equipment Company Limited, Double Medical Technology Inc. is headquartered in Xiamen, People's Republic of China.

Company Valuation

Overvalued
2/7

Considering past and projected metrics, the stock is 'expensive' compared to its peers. Specifically, the stock is fairly valued on P/E, overvalued on EV/EBITDA, overpric

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Neutral
4/7

The average target price of 002901.SZ is 43.2 and suggests 3.57% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

14.07.2026 16:04

"Records Across the Board": JPMorgan Reports a 41% Increase in Quarterly Profit

14.07.2026 15:48

Morning in New York: News Flow Will Drive Volatility

14.07.2026 14:41

Shares of a small-cap AI solutions developer soared amid a sector-wide slump. Why?

14.07.2026 13:30

Risks for a neobank: Can Revolut Reach a $200 Billion Valuation?

14.07.2026 12:58

Following SK Hynix, Samsung has approved the listing of its securities in the U.S. — Bloomberg

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026